BioNTech SE announced on Tuesday that its revenue in the third quarter of fiscal 2026 declined 15% year over year to €1.29 billion. The figure did land above market expectations.The pharmaceutical com...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Mainz – Just a few weeks before the announced departure of co-founders Ugur Sahin and Özlem Türeci, Biontech reported a profit for the third quarter. Nevertheless, a billion loss is due for the first nine months of 2026. According to its own figures, the third quarter closed with a net profit of 184.5 million euros...
(Teleborsa) - BioNTech moves towards a tonic session with the title that rises by more than 2% in the Wall Street pre-market after the accounts beyond expectations and having revised its turnover forecast upwards...